Overview Marqibo® Alocrest™ Brakiva™ Menadione Topical Lotion Hana Clinical Trials Publications Presentations Click here to watch the Mechanism of Action video Click here for rALLy details		Marqibo® (vincristine sulfate liposome injection, OPTISOME™) A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound for Acute Lymphoblastic Leukemia (ALL) and Melanoma Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin's lymphoma (NHL) and ALL. Hana has ongoing (or planned) clinical trials which may enable an accelerated approval in two indications. They are: Global, registration-enabling, Phase 2 trial in adult patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia in second relapse (rALLy Trial) Confirmatory Phase 3 trial evaluating Marqibo versus standard vincristine in combination therapy in the front line treatment of newly diagnosed elderly (≥ 60 yrs) Ph- acute lymphoblastic leukemia (ALLy Trial) Phase 2 trial in patients with metastatic uveal melanoma, a rare, rapidly progressing form of melanoma with distinct patterns of metastatic spread Ongoing Trials Phase II: Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia (rALLy) Phase II: Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma Publications ASH 2007 – Relapsed ALL ASH 2007 Preclinical AACR-NCI-EORTC ASCO 2007 – Uveal For further information on our product pipeline and/or business development inquiries please contact the Business Development Department.
© 2010 Hana Biosciences. Web design by Global 1 Design.